Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cold agglutinin disease
Paul Swiecicki, Livia Hegerova, Morie A. Gertz
Blood (2013) Vol. 122, Iss. 7, pp. 1114-1121
Open Access | Times Cited: 289

Showing 1-25 of 289 citing articles:

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, et al.
Leukemia (2022) Vol. 36, Iss. 7, pp. 1720-1748
Open Access | Times Cited: 2321
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jäger, Wilma Barcellini, Catherine M. Broome, et al.
Blood Reviews (2019) Vol. 41, pp. 100648-100648
Open Access | Times Cited: 399
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni, et al.
Blood (2014) Vol. 124, Iss. 19, pp. 2930-2936
Open Access | Times Cited: 309
Treatment of autoimmune hemolytic anemias
Alberto Zanella, Wilma Barcellini
Haematologica (2014) Vol. 99, Iss. 10, pp. 1547-1554
Open Access | Times Cited: 243
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Jean-Paul Fermand, Frank Bridoux, Angela Dispenzieri, et al.
Blood (2018) Vol. 132, Iss. 14, pp. 1478-1485
Open Access | Times Cited: 237
The diagnosis and management of primary autoimmune haemolytic anaemia
Quentin A. Hill, R. Stamps, Edwin Massey, et al.
British Journal of Haematology (2016) Vol. 176, Iss. 3, pp. 395-411
Open Access | Times Cited: 215
How I treat autoimmune hemolytic anemia
Ronald S. Go, Jeffrey L. Winters, Neil E. Kay
Blood (2017) Vol. 129, Iss. 22, pp. 2971-2979
Open Access | Times Cited: 174
Novel insights into the treatment of complement-mediated hemolytic anemias
Sigbjørn Berentsen, Anita Hill, Quentin A. Hill, et al.
Therapeutic Advances in Hematology (2019) Vol. 10
Open Access | Times Cited: 161
Sutimlimab in Cold Agglutinin Disease
Alexander Röth, Wilma Barcellini, Shirley D’Sa, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 14, pp. 1323-1334
Open Access | Times Cited: 156
Autoimmune Hemolytic Anemias
Sigbjørn Berentsen, Wilma Barcellini
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1407-1419
Closed Access | Times Cited: 140
New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia
Wilma Barcellini
Transfusion Medicine and Hemotherapy (2015) Vol. 42, Iss. 5, pp. 287-293
Open Access | Times Cited: 153
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi, Eileen L. Rose, Andrew Singh, et al.
Blood (2014) Vol. 123, Iss. 26, pp. 4015-4022
Open Access | Times Cited: 141
Diagnosis and classification of autoimmune hemolytic anemia
Garrett Bass, Emily Tuscano, Joseph M. Tuscano
Autoimmunity Reviews (2014) Vol. 13, Iss. 4-5, pp. 560-564
Closed Access | Times Cited: 123
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, et al.
Blood (2020) Vol. 136, Iss. 4, pp. 480-488
Open Access | Times Cited: 123
Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies
Quitterie Reynaud, I. Durieu, M. Dutertre, et al.
Autoimmunity Reviews (2014) Vol. 14, Iss. 4, pp. 304-313
Closed Access | Times Cited: 120
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjørn Berentsen
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 120
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjørn Berentsen, Ulla Randen, Markku Oksman, et al.
Blood (2017) Vol. 130, Iss. 4, pp. 537-541
Open Access | Times Cited: 113
How I manage monoclonal gammopathy of undetermined significance
Ronald S. Go, S. Vincent Rajkumar
Blood (2017) Vol. 131, Iss. 2, pp. 163-173
Open Access | Times Cited: 112
Cold agglutinin disease
Sigbjørn Berentsen
Hematology (2016) Vol. 2016, Iss. 1, pp. 226-231
Open Access | Times Cited: 101
How I manage patients with cold agglutinin disease
Sigbjørn Berentsen
British Journal of Haematology (2018) Vol. 181, Iss. 3, pp. 320-330
Open Access | Times Cited: 98
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, et al.
Blood (2018) Vol. 133, Iss. 9, pp. 893-901
Open Access | Times Cited: 98
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment
Quentin A. Hill, Anita Hill, Sigbjørn Berentsen
Blood Advances (2019) Vol. 3, Iss. 12, pp. 1897-1906
Open Access | Times Cited: 98
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjørn Berentsen, Ulla Randen, Geir E. Tjønnfjord
Hematology/Oncology Clinics of North America (2015) Vol. 29, Iss. 3, pp. 455-471
Closed Access | Times Cited: 97
How I treat cold agglutinin disease
Sigbjørn Berentsen
Blood (2021) Vol. 137, Iss. 10, pp. 1295-1303
Open Access | Times Cited: 93
Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for Therapy
Sigbjørn Berentsen, Tatjana Sundic
BioMed Research International (2015) Vol. 2015, pp. 1-11
Open Access | Times Cited: 92
Page 1 - Next Page

Scroll to top